Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.50
SRPT's Cash-to-Debt is ranked lower than
70% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. SRPT: 2.50 )
Ranked among companies with meaningful Cash-to-Debt only.
SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.5  Med: 5077.03 Max: No Debt
Current: 2.5
2.5
No Debt
Equity-to-Asset 0.60
SRPT's Equity-to-Asset is ranked lower than
60% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SRPT: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
SRPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.84 Max: 0.97
Current: 0.6
-0.06
0.97
Debt-to-Equity 0.55
SRPT's Debt-to-Equity is ranked lower than
70% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SRPT: 0.55 )
Ranked among companies with meaningful Debt-to-Equity only.
SRPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68  Med: 0.06 Max: 0.55
Current: 0.55
-0.68
0.55
Debt-to-EBITDA -12.34
SRPT's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. SRPT: -12.34 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SRPT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -0.08 Max: -0.02
Current: -12.34
-12.4
-0.02
Piotroski F-Score: 3
Altman Z-Score: 5.75
Beneish M-Score: 21.41
WACC vs ROIC
14.14%
-162.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -90.92
SRPT's Operating Margin % is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. SRPT: -90.92 )
Ranked among companies with meaningful Operating Margin % only.
SRPT' s Operating Margin % Range Over the Past 10 Years
Min: -17572.55  Med: -89.5 Max: -71.16
Current: -90.92
-17572.55
-71.16
Net Margin % -32.79
SRPT's Net Margin % is ranked higher than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. SRPT: -32.79 )
Ranked among companies with meaningful Net Margin % only.
SRPT' s Net Margin % Range Over the Past 10 Years
Min: -17560.26  Med: -233.99 Max: -4.93
Current: -32.79
-17560.26
-4.93
ROE % -9.64
SRPT's ROE % is ranked higher than
69% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. SRPT: -9.64 )
Ranked among companies with meaningful ROE % only.
SRPT' s ROE % Range Over the Past 10 Years
Min: -309.2  Med: -100.95 Max: -9
Current: -9.64
-309.2
-9
ROA % -7.25
SRPT's ROA % is ranked higher than
70% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. SRPT: -7.25 )
Ranked among companies with meaningful ROA % only.
SRPT' s ROA % Range Over the Past 10 Years
Min: -93.53  Med: -59.76 Max: -4.62
Current: -7.25
-93.53
-4.62
ROC (Joel Greenblatt) % -60.43
SRPT's ROC (Joel Greenblatt) % is ranked higher than
68% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. SRPT: -60.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SRPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -978.9  Med: -512.65 Max: -57.75
Current: -60.43
-978.9
-57.75
3-Year Revenue Growth Rate 120.80
SRPT's 3-Year Revenue Growth Rate is ranked higher than
96% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SRPT: 120.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SRPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.3  Med: 9.1 Max: 343.4
Current: 120.8
-73.3
343.4
3-Year EBITDA Growth Rate 43.30
SRPT's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SRPT: 43.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SRPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.7  Med: -3.6 Max: 43.3
Current: 43.3
-61.7
43.3
3-Year EPS without NRI Growth Rate 36.70
SRPT's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SRPT: 36.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SRPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -213.5  Med: 0 Max: 62.2
Current: 36.7
-213.5
62.2
GuruFocus has detected 7 Warning Signs with Sarepta Therapeutics Inc SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SRPT's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

SRPT Guru Trades in Q1 2017

John Paulson 78,101 sh (New)
Paul Tudor Jones 80,929 sh (New)
Jim Simons 86,078 sh (+75.39%)
Louis Moore Bacon Sold Out
Steven Cohen 803,300 sh (-41.26%)
» More
Q2 2017

SRPT Guru Trades in Q2 2017

Steven Cohen 2,025,406 sh (+152.14%)
Jim Simons Sold Out
John Paulson Sold Out
Paul Tudor Jones 27,517 sh (-66.00%)
» More
Q3 2017

SRPT Guru Trades in Q3 2017

Ken Fisher 42,642 sh (New)
Joel Greenblatt 9,268 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen 1,645,275 sh (-18.77%)
» More
Q4 2017

SRPT Guru Trades in Q4 2017

Ken Fisher 42,648 sh (+0.01%)
Steven Cohen 200,000 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 579,757 sh (-64.76%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 34.66%$54.02 - $82.27 $ 78.5518%57,431
Ken Fisher 2017-12-31 Add 0.01%$47.64 - $56.75 $ 78.5548%42,648
Joel Greenblatt 2017-12-31 Sold Out 0.01%$47.64 - $56.75 $ 78.5548%0
Ken Fisher 2017-09-30 New Buy$33.89 - $47.15 $ 78.5597%42,642
Joel Greenblatt 2017-09-30 New Buy0.01%$33.89 - $47.15 $ 78.5597%9,268
John Paulson 2017-06-30 Sold Out 0.03%$28.41 - $36.72 $ 78.55142%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Sarepta Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:128940, BOM:532523, HKSE:01548, HKSE:01530, SZSE:000661, NAS:TECH, NAS:AGIO, OSTO:SOBI, NAS:UTHR, NAS:AVXS, TSE:4587, NAS:BPMC, NAS:IONS, SZSE:002007, XBRU:ABLX, SHSE:600201, XKRX:215600, NAS:FGEN, SZSE:300347, NAS:AAAP » details
Traded in other countries:AB3A.Germany,
Headquarter Location:USA
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Top Ranked Articles about Sarepta Therapeutics Inc

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Sarepta Is Like the Tesla of Biotech Sarepta Therapeutics has exploded higher since last year on the hopes that its Duchenne muscular dystrophy drug is effective and insurance will keep covering it. Much like Tesla, its stock price is fu
Sarepta Therapeutics (NASDAQ:SRPT) has been one of the most rewarding biotech investments since the beginning of 2017. I consider it the Tesla Inc. (NASDAQ:TSLA) of the biotech industry. That’s a good thing as long as investors remain infatuated with the idea of a new company with a revolutionary product that has not yet proven itself in the marketplace. Could the company actually make money? Of course, but that's not currently why its market caps is so high. Read more...
New Research: Key Drivers of Growth for Morgan Stanley, Novavax, Xerox, Sarepta Therapeutics, Semgroup, and Toll Brothers — Factors of Influence, Major Initiatives and Sustained Production
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018
Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy
Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth

Ratios

vs
industry
vs
history
PB Ratio 6.45
SRPT's PB Ratio is ranked lower than
59% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SRPT: 6.45 )
Ranked among companies with meaningful PB Ratio only.
SRPT' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 5.47 Max: 238.78
Current: 6.45
2
238.78
PS Ratio 30.51
SRPT's PS Ratio is ranked lower than
66% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SRPT: 30.51 )
Ranked among companies with meaningful PS Ratio only.
SRPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 23.23 Max: 39930
Current: 30.51
1.56
39930
EV-to-EBIT -103.61
SRPT's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. SRPT: -103.61 )
Ranked among companies with meaningful EV-to-EBIT only.
SRPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -107.75  Med: -5.7 Max: -1.1
Current: -103.61
-107.75
-1.1
EV-to-EBITDA -127.62
SRPT's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. SRPT: -127.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.72  Med: -6 Max: -1.1
Current: -127.62
-132.72
-1.1
EV-to-Revenue 28.80
SRPT's EV-to-Revenue is ranked lower than
62% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. SRPT: 28.80 )
Ranked among companies with meaningful EV-to-Revenue only.
SRPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 19.5 Max: 58632.1
Current: 28.8
0.8
58632.1
Current Ratio 13.91
SRPT's Current Ratio is ranked higher than
89% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SRPT: 13.91 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 7.52 Max: 35.4
Current: 13.91
0.83
35.4
Quick Ratio 12.96
SRPT's Quick Ratio is ranked higher than
88% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. SRPT: 12.96 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 7.52 Max: 35.4
Current: 12.96
0.83
35.4
Days Inventory 2.00
SRPT's Days Inventory is ranked higher than
95% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. SRPT: 2.00 )
Ranked among companies with meaningful Days Inventory only.
SRPT' s Days Inventory Range Over the Past 10 Years
Min: 2  Med: 12772.64 Max: 23152.2
Current: 2
2
23152.2
Days Sales Outstanding 69.58
SRPT's Days Sales Outstanding is ranked lower than
53% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. SRPT: 69.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 77.47 Max: 1158.5
Current: 69.58
28.22
1158.5
Days Payable 417.07
SRPT's Days Payable is ranked higher than
93% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. SRPT: 417.07 )
Ranked among companies with meaningful Days Payable only.
SRPT' s Days Payable Range Over the Past 10 Years
Min: 417.07  Med: 53857.92 Max: 107295.54
Current: 417.07
417.07
107295.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.20
SRPT's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SRPT: -16.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -20.4 Max: -11.6
Current: -16.2
-27.6
-11.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.08
SRPT's Price-to-Net-Cash is ranked higher than
55% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. SRPT: 9.08 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.36  Med: 6.48 Max: 28.21
Current: 9.08
3.36
28.21
Price-to-Net-Current-Asset-Value 7.17
SRPT's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. SRPT: 7.17 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.98  Med: 5.37 Max: 12.49
Current: 7.17
2.98
12.49
Price-to-Tangible-Book 6.57
SRPT's Price-to-Tangible-Book is ranked lower than
52% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. SRPT: 6.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.47  Med: 4.42 Max: 9.58
Current: 6.57
2.47
9.58
Price-to-Median-PS-Value 1.31
SRPT's Price-to-Median-PS-Value is ranked lower than
61% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. SRPT: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 2.66 Max: 63.6
Current: 1.31
0.09
63.6
Earnings Yield (Greenblatt) % -0.95
SRPT's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. SRPT: -0.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -94.6  Med: -17.6 Max: -0.91
Current: -0.95
-94.6
-0.91

More Statistics

Revenue (TTM) (Mil) $154.58
EPS (TTM) $ -0.82
Beta1.97
Volatility39.12%
52-Week Range $28.82 - 84.37
Shares Outstanding (Mil)64.98

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 312 564 766
EBIT (Mil $) -57 149 359
EBITDA (Mil $) -50 160 379
EPS ($) -0.95 1.74 4.42
EPS without NRI ($) -0.95 1.74 4.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}